Newsletter Volume 40, Number 3, 2025
Introduction
The year 2025 is fast approaching its turn. This year, the rainy season starts later than usual, and temperatures from June to August are said to be higher than usual nationwide, making it more important to take measures against heat stroke this summer.
Looking back on the first half of this year, we asked AI what will be the most impressive event in Japan in 2025, and the answer was the Osaka-Kansai Expo. As you all know, the theme of the Osaka-Kansai Expo is “Designing Future Society for Our Lives” (Designing Future Society for Our Lives), where cutting-edge technologies and other world wisdom will be brought together to create and disseminate new ideas. This is one of the efforts to realize Japan’s national strategy, “Society 5.0,” or “a human-centered society that balances economic development and solutions to social issues through a system that highly integrates cyberspace (virtual space) and physical space (real space). I sometimes wonder what life will be like 20 years from now, given the extremely fast pace of scientific development in recent years, including the use of AI, IoT, and big data. I have not yet had the opportunity to attend the Expo because I live in the Kanto region of Japan, but I hope to attend the Expo with my children before it closes and have a chance to experience a part of the future society through the Expo.
Through the sharing of the latest research results and reports on the activities of our society in this newsletter, we hope to provide you with useful information so that you can keep up, and sometimes even stay ahead, of the global pace of scientific progress. Please take a look at this issue of the newsletter for its rich contents. (S.K.)
Topics
Pharmacokinetic Society of Japan Newsletter: Regulatory Science Information
The Newsletter Committee reports on regulatory science information related to the field of pharmacokinetics, including the latest trends in guidelines and regulatory harmonization activities at ICH. … (To be continued at NL website / members only)
NEW POWER for pharmacokinetic research
Toward Optimizing Pharmacotherapy in Special Populations
Oita University Hospital Pharmacy
Ryota Tanaka
My name is Ryohiro Tanaka and I am with the Department of Pharmacy, Oita University Hospital. I would like to express my sincere gratitude to the editorial board members and all those involved for the opportunity to contribute to the newsletter of the Japanese Pharmacokinetics Society, “New Power for Pharmacokinetics Research. I joined the Department of Pharmacy, Oita University Hospital in April 2014 after completing the doctoral course at Kumamoto University Graduate School. I was engaged in basic pharmacological research using animals and cells during graduate school, but after joining the department, I have worked as a clinical pharmacist mainly in the promotion of appropriate use of antimicrobial agents, therapeutic drug monitoring (TDM), and drug information management (DI) to ensure appropriate drug therapy. … (To be continued at NL website / members only)
Pharmacokinetics of targeted protein degraders (TPDs)
Part 3: Factors affecting PK/PD interpretation of bifunctional protein degraders
Translational & Biomedical Science, Astellas Pharma Inc.
Fumio Osaki
Continuing on from the previous article, I would like to write about “targeted protein degraders (TPDs)” as the third part of an introduction to pharmacokinetic research in R&D of new modality. TPD is a new “small molecule” modality that has attracted much attention, mainly in the field of oncology. In this three-part series, we introduce how to evaluate the characteristics of TPD from the viewpoint of pharmacokinetics and translational research, and how to predict its efficacy in clinical practice. In the third article, we will focus on the factors that influence the interpretation of PKPD for Bifunctional protein degrader, a type of TPD, in the literature. … (To be continued at NL website / members only)